Guido Dalbagni

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery
    Bradley Andrew Morganstern
    Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461, USA
    Health Qual Life Outcomes 9:10. 2011
  2. ncbi request reprint Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer
    G Dalbagni
    Urology Service, Department of Surgery, Laboratories of Developmental Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 3:1593-8. 1997
  3. doi request reprint Bladder cancer: Restaging TUR reduces recurrence and progression risk
    Guido Dalbagni
    Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, New York, NY 10021, USA
    Nat Rev Urol 7:649-50. 2010
  4. ncbi request reprint The management of superficial bladder cancer
    Guido Dalbagni
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 4:254-60. 2007
  5. ncbi request reprint Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
  6. doi request reprint A plea for a uniform surveillance schedule after radical cystectomy
    Guido Dalbagni
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 185:2091-6. 2011
  7. ncbi request reprint Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
  8. doi request reprint Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer
    Guido Dalbagni
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 56:903-10. 2009
  9. ncbi request reprint Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study
    G Dalbagni
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 7:2797-801. 2001
  10. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008

Detail Information

Publications81

  1. pmc The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery
    Bradley Andrew Morganstern
    Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461, USA
    Health Qual Life Outcomes 9:10. 2011
    ..Our evaluation of this measure is a prelude to a prospective comparison of quality of life outcomes of reconstructive procedures after cystectomy...
  2. ncbi request reprint Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer
    G Dalbagni
    Urology Service, Department of Surgery, Laboratories of Developmental Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 3:1593-8. 1997
    ..The TRAP assay is reproducible, highly specific, and not dependent on the expertise of the cytopathologist. These results suggest that this assay should be further investigated as a diagnostic tool for bladder cancer...
  3. doi request reprint Bladder cancer: Restaging TUR reduces recurrence and progression risk
    Guido Dalbagni
    Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, New York, NY 10021, USA
    Nat Rev Urol 7:649-50. 2010
    ..A recent study has confirmed that a second, or restaging, TUR is associated with a lower risk of progression and cancer-related death. Restaging TUR is therefore recommended as a standard of care in patients with stage T1 bladder cancer...
  4. ncbi request reprint The management of superficial bladder cancer
    Guido Dalbagni
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 4:254-60. 2007
    ..The effect of intravesical immunotherapy in bladder cancer is explored as well as the role of early cystectomy...
  5. ncbi request reprint Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  6. doi request reprint A plea for a uniform surveillance schedule after radical cystectomy
    Guido Dalbagni
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 185:2091-6. 2011
    ..We identified the pattern of post-cystectomy surveillance recommended in the oncologic community and assessed compliance to a predetermined schedule among a small group of urologists...
  7. ncbi request reprint Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
    ..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
  8. doi request reprint Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer
    Guido Dalbagni
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 56:903-10. 2009
    ..To evaluate the indications for early and deferred cystectomy and to report the impact of this tailored approach on survival...
  9. ncbi request reprint Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study
    G Dalbagni
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 7:2797-801. 2001
    ..We postulated that if tumor cells at different points in the natural history of the disease contain an identical mutation in the TP53 gene, this pattern could provide evidence for the monoclonality of the recurrent bladder tumors...
  10. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  11. pmc Metastatic renal cell carcinoma risk according to tumor size
    R Houston Thompson
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 182:41-5. 2009
    ..We present our experience with renal cell carcinoma. We evaluated the association between tumor size and the metastasis risk in a large patient cohort...
  12. doi request reprint Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  13. doi request reprint Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?
    Ricardo L Favaretto
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    Eur Urol 58:645-51. 2010
    ..Questions remain regarding the oncologic safety of LRN and its relative equivalence to ORN...
  14. doi request reprint Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma
    Behfar Ehdaie
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 111:589-95. 2013
    ..In addition, competing risks analyses showed that although current smoking did not increase the risk of recurrence, it imparted a significant risk of dying compared with former and never smoking...
  15. doi request reprint Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma
    Ricardo L Favaretto
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 109:77-82. 2012
    ....
  16. doi request reprint Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer
    David S Yee
    Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 183:1751-6. 2010
    ..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
  17. ncbi request reprint Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:2167-72. 2006
    ..In an attempt to reduce this recurrence risk, urologists employ intraoperative frozen sections to achieve an uninvolved ureteral margin. The utility of this surgical approach was examined...
  18. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival...
  19. ncbi request reprint Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1283-6; discussion 1286. 2007
    ..In this study we explored the effect of this paradigm shift on progression rates and disease specific survival...
  20. ncbi request reprint Natural history of positive urinary cytology after radical cystectomy
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:2000-5; discussion 2005. 2006
    ..The natural history and risk of disease progression in patients with positive urine cytology after radical cystectomy for urothelial carcinoma has not been adequately elucidated...
  21. ncbi request reprint Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy
    Joseph A Pettus
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 53:370-5. 2008
    ....
  22. doi request reprint Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer
    Theresa M Koppie
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 112:2384-92. 2008
    ..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics...
  23. doi request reprint The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center
    Ricardo L Favaretto
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 58:574-80. 2010
    ..The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious...
  24. ncbi request reprint Carcinoma in a bladder diverticulum: presentation and treatment outcome
    Dragan Golijanin
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 170:1761-4. 2003
    ..In this retrospective review we characterize the outcomes of patients treated for transitional cell carcinoma in a bladder diverticulum...
  25. doi request reprint Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy
    Matthew G Kaag
    Department of Surgery, Urology Section, Memorial Sloan Kettering Cancer Center, 1275 York Ave Box 213, New York, NY 10065, USA
    BJU Int 108:E272-7. 2011
    ..To evaluate the effect of preoperative cisplatin-based chemotherapy on the regional lymph nodes of patients with bladder cancer who attain pathological T0 status in the bladder after chemotherapy followed by radical cystectomy...
  26. doi request reprint Clinical outcome of primary versus secondary bladder carcinoma in situ
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:464-9. 2010
    ..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
  27. doi request reprint Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma
    Guido Dalbagni
    The Division of Urology and Division of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NewYork, NY, USA
    BJU Int 106:1502-7. 2010
    ..To report the heterogeneity in the treatment of patients with cT1 urothelial carcinoma by different surgeons, and to report outcomes in patients with and without bacillus Calmette-Guérin (BCG) treatment...
  28. ncbi request reprint Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance
    William Tran
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:96-100. 2008
    ..However, these recurrence rates are based on statistical methodology that does not take censoring into account. We used landmark time analysis to determine whether the risk of upper tract recurrence changes over time...
  29. doi request reprint Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity
    Tatum V Tarin
    Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Eur Urol 61:1025-30. 2012
    ..The extent of lymphadenectomy needed to optimize oncologic outcomes after radical cystectomy (RC) for patients with regionally advanced bladder cancer (BCa) is unclear...
  30. ncbi request reprint Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:1286-90. 2004
    ..We prospectively evaluated RC cases with transitional cell carcinoma of the bladder to determine which factors may contribute to the variability in the number of reported LNs...
  31. ncbi request reprint Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?
    Theresa M Koppie
    Department of Urology, Sidney Kimmel Center for Urologic Cancer, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:2368-74. 2006
    ..The goal of the current study was to determine if a threshold number of nodes exists, above which taking additional LNs has no clinical benefit...
  32. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..This study analyzes the outcomes of partial cystectomy in a contemporary cohort of patients to identify appropriate selection criteria for the procedure...
  33. doi request reprint Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer
    Joshua J Meeks
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 111:E325-30. 2013
    ..To describe the pathological outcomes of patients with muscle-invasive micropapillary bladder cancer who have undergone neoadjuvant chemotherapy...
  34. ncbi request reprint Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:177-81. 2003
    ..The impact of orthotopic urinary diversion on the quality of cystectomy and ensuing cancer control has not been adequately studied. We analyzed our experience with this clinical problem...
  35. doi request reprint Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
    David J Gallagher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 115:5193-201. 2009
    ..The objective of this study was to evaluate the feasibility and survival impact of adjuvant, sequential chemotherapy in patients with high-risk UC...
  36. pmc Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach
    Andrew J Vickers
    Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 115:5460-9. 2009
    ....
  37. pmc Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma
    Jonathan L Silberstein
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 187:429-34. 2012
    ..We compared renal function and oncologic outcomes of parenchymal sparing ureteral resection with radical nephroureterectomy for the treatment of upper tract urothelial carcinoma confined to the ureter...
  38. ncbi request reprint Urachal carcinoma: contemporary surgical outcomes
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:74-8; discussion 78. 2007
    ..We determined surgical outcomes in a contemporary series of patients who underwent surgery for urachal carcinoma...
  39. ncbi request reprint Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments
    Dipen J Parekh
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5519-27. 2006
    ..Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy...
  40. ncbi request reprint Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases
    Semra Olgac
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 28:1545-52. 2004
    ..Pathologic stage is the most potent predictor of survival, similar to lower tract disease. A subset of the cases could not be staged due to processing issues; we thus recommend fixation prior to prosecting...
  41. pmc Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy
    Matthew G Kaag
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 58:581-7. 2010
    ..Nephroureterectomy alone fails to adequately treat many patients with advanced upper tract urothelial carcinoma (UTUC). Perioperative platinum-based chemotherapy has been proposed but requires adequate renal function...
  42. ncbi request reprint Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer
    Jaspreet S Sandhu
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    BJU Int 98:59-62. 2006
    ....
  43. ncbi request reprint Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:482-5. 2006
    ..We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients...
  44. ncbi request reprint Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:281-5. 2007
    ....
  45. doi request reprint Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection
    Itay A Sternberg
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 112:54-9. 2013
    ..Thus, immediate RC should be considered in all patients with T1 bladder cancer and residual T1 on re-TURBT...
  46. doi request reprint Urinary diversion practice patterns among certifying American urologists
    Jonathan L Silberstein
    Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York 10065, USA
    J Urol 189:1042-7. 2013
    ..We investigated trends in urinary diversion use and surgeon characteristics in the performance of incontinent and continent urinary diversion using American Board of Urology data...
  47. ncbi request reprint Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Atreya Dash
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:506-13. 2006
    ..Renal impairment may be a major factor limiting its use. The current study was designed to determine the proportion of patients ineligible to receive adjuvant cisplatin-based chemotherapy based on inadequate renal function alone...
  48. doi request reprint Update on intravesical agents for non-muscle-invasive bladder cancer
    Shahrokh F Shariat
    Urology Service, Memorial Sloan Kettering Cancer Center, NY, USA
    Immunotherapy 2:381-92. 2010
    ..Combination intravesical therapy may be more successful than single-agent strategies. Intravesical therapy failures indicate the need to include radical cystectomy as an option in the management decision...
  49. ncbi request reprint Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
    Harry W Herr
    Departments of Urology Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 167:1295-8. 2002
    ..We postulate that the number of lymph nodes examined in cystectomy specimens can have an impact on the outcome of patients with bladder cancer...
  50. doi request reprint Upper Tract Imaging Surveillance is not Effective in Diagnosing Upper Tract Recurrence in Patients Followed for Nonmuscle Invasive Bladder Cancer
    Itay A Sternberg
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Urol 190:1187-91. 2013
    ..We evaluated the usefulness of routine upper tract imaging in patients followed for nonmuscle invasive bladder cancer...
  51. doi request reprint Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 111:984-7. 2013
    ....
  52. doi request reprint Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters
    Preston C Sprenkle
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 61:593-9. 2012
    ..Indications for partial nephrectomy (PN) in the treatment of renal cell carcinoma are evolving, particularly for larger, more complex tumors...
  53. ncbi request reprint Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis
    Dragan Golijanin
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Clin Cancer Res 10:1024-31. 2004
    ..Because human papillomavirus (HPV) has been linked to the development of penile SCC, a secondary objective was to determine whether COX-2 was overexpressed in SCC arising in an HPV16 transgenic mouse...
  54. ncbi request reprint Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:75-9; discussion 79. 2007
    ..We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer...
  55. ncbi request reprint Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy
    Daniel W Lin
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 169:961-3. 2003
    ..We retrospectively evaluated the outcome in post-cystectomy urethrectomy cases at our institution from 1994 to 2000...
  56. ncbi request reprint Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 168:978-80. 2002
    ....
  57. doi request reprint Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology
    Ahmad Shabsigh
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:164-74. 2009
    ..Reporting methodology is highly variable and nonstandardized, yet surgical outcomes are utilized in clinical trial design and evaluation of healthcare provider performance...
  58. ncbi request reprint Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods
    Ming Lan Lu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:171-9. 2002
    ..015), and it appears to be a significant prognostic factor associated with patient survival...
  59. ncbi request reprint Impact of a second transurethral resection on the staging of T1 bladder cancer
    Guido Dalbagni
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 60:822-4; discussion 824-5. 2002
    ..To evaluate the impact of a second transurethral resection (TUR) on the pathologic stage in a unique patient population with T1 tumors...
  60. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  61. ncbi request reprint Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study
    Badrinath R Konety
    Department of Urology, Memorial Sloan Kettering Cancer Center and Cornell University, New York, New York 10021, USA
    J Urol 171:709-13. 2004
    ....
  62. ncbi request reprint Role of voided urine cytology in diagnosing primary urethral carcinoma
    A Karim Touijer
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 63:33-5. 2004
    ..To evaluate the role of voided urine cytology in diagnosing primary carcinoma of the urethra in male and female patients...
  63. pmc Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
    Hikmat A Al-Ahmadie
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
    J Pathol 224:270-9. 2011
    ..Histological review could thus aid in the development of targeted inhibitors of FGFR-3 by facilitating the identification of the subset of patients most likely to harbour activating mutations in the FGFR3 gene...
  64. doi request reprint Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 106:1499-501. 2010
    ....
  65. doi request reprint Reflex UroVysion testing in suspicious urine cytology cases
    Susana Ferra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 117:7-14. 2009
    ..The rationale was that a more aggressive workup might be indicated in patients with a suspicious cytology diagnosis and positive UroVysion test...
  66. ncbi request reprint Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer?
    Jason Hafron
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 173:1513-7. 2005
    ..Obesity is estimated to account for up to 20% of all cancer deaths. We evaluated the effect of body mass index (BMI) on survival in patients undergoing radical or partial cystectomy for bladder cancer...
  67. doi request reprint Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:177-85. 2009
    ..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...
  68. ncbi request reprint Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 175:2038-41; discussion 2041. 2006
    ..Because nontransitional cell carcinoma neoplasms of the urinary tract are rare in Western countries, we examined the association between urinary cytology and pathology evaluations for these tumors...
  69. ncbi request reprint Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review
    Daher C Chade
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int Braz J Urol 35:640-50; discussion 651. 2009
    ..Future perspectives and promising advances in drug development are discussed and areas of improvement are identified in order to promote better cancer control and decrease the rate and severity of side-effects...
  70. ncbi request reprint Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 168:61-6. 2002
    ..The natural history and prognosis of bladder cancer in young patients is not well defined. We analyzed our experience with such patients...
  71. pmc Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability
    Harry Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 106:53-5. 2010
    ..Diagnosis (exploratory cohort) Level of Evidence 2b...
  72. pmc Contemporary use of partial nephrectomy at a tertiary care center in the United States
    R Houston Thompson
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 181:993-7. 2009
    ..The use of partial nephrectomy for renal cortical tumors appears unacceptably low in the United States according to population based data. We examined the use of partial nephrectomy at our tertiary care facility in the contemporary era...
  73. ncbi request reprint Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases
    Oscar Lin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 16:1289-98. 2003
    ..Nevertheless, p53, bcl-2, or EGF-r immunoreactivity is not frequently seen...
  74. ncbi request reprint Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:636-9. 2004
    ..We report our experience with office fulguration of small, recurrent, low grade papillary tumors using flexible cystodiathermy...
  75. ncbi request reprint Defining bacillus Calmette-Guerin refractory superficial bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:1706-8. 2003
    ..We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer...
  76. ncbi request reprint Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development
    Gloria E Mao
    Department of Epidemiology, School of Public Health, University of California Los Angeles, Los Angeles, CA, USA
    Cancer Epidemiol Biomarkers Prev 13:383-90. 2004
    ..These findings suggest that chemoprevention strategies with retinoids may be most effective if applied during the early stages of transformation...
  77. ncbi request reprint Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
    M Craig Hall
    American Urological Association Education and Research, Inc, USA
    J Urol 178:2314-30. 2007
  78. ncbi request reprint Comparison of bladder cancer survival among Japanese, Chinese, Filipino, Hawaiian and Caucasian populations in the United States
    Mia Hashibe
    Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA 90095 1772, USA
    Asian Pac J Cancer Prev 4:267-73. 2003
    ..The purpose of this study was to compare the bladder cancer survival rates of Japanese, Chinese, Filipinos, Hawaiians and Caucasians in the U.S. population...
  79. ncbi request reprint Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma
    Wei Cao
    Department of Epidemiology, UCLA School of Public Health, and Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 1772, USA
    Cancer 104:2400-8. 2005
    ..GSTP1 may play a role in detoxification of tobacco-related carcinogens...
  80. ncbi request reprint Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer
    Gloria E Mao
    Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA 90095, USA
    Cancer Detect Prev 28:368-74. 2004
    ..52 (95% CI: 1.07-19.17). To our knowledge, this is the first time that a potential effect modification by the GSTP1 Ile/Ile genotype on smoking and the risk of prostate cancer is suggested...
  81. ncbi request reprint Overview of bladder cancer trials in the Cancer and Leukemia Group B
    Eric J Small
    Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 97:2090-8. 2003
    ..Novel agents, including arsenic trioxide and trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), are being evaluated as secondline therapy in patients with advanced TCC who have disease progression after frontline therapy...